Newspatrolling.com News cum Content Syndication Portal Online
Hyderabad, India – 3 March2025–NeovantageInnovationPark,the largest private owner and operator oflifesciencesinfrastructurein South Asia, marked a significant presence atBioAsia2025, underscoring its commitment to fostering a world-classlifesciencesinfrastructurein Telangana.
As part of its participation atBioAsia,NeovantageInnovationParkhosted a delegation fromBioAsiafor an exclusive sitevisit. The delegation consisted of governmental and industry delegates includingSh. Jayesh Ranjan, IAS, Special Chief Secretary IT&EC and Department of Commerce and Industries, Sh. Shakthi Nagappan, CEO TelanganaLifeSciences, Dr. Kathrin Misera-Lang, Consul General for Germany, Ms. Amita Desai, Honorary Consul for Germany. ThevisitshowcasedBuilding 3600 and facilities designed to house leading biotech andlifesciencescompanies. Theparkhas recently welcomed several pioneering tenants, further cementing its position as a hub for scientific breakthroughs.
A key highlight of thevisitwas theinaugurationof theMiltenyiInnovationand Technology Center, a CGT Centre of Excellence (COE). The center is the first of its kind inIndiafor cutting-edge cell and gene therapy research and manufacturing. The launch represents a major milestone inIndiaֱ journey toward advanced biopharmaceuticalinnovation, reinforcing Telanganaֱ reputation as a leadinglifesciencesdestination.Miltenyiwas represented byDr. Boris Stoffel , CEO,MiltenyiBiotech, Ms. Priya Hingorani, Managing Director,MiltenyiBiotecIndiaand their senior management team and employees. Theinaugurationwas followed by tree planting ceremony in the campus.
“We are proud to contribute to the growth of Indiaֱlifesciencessector by providing world-classinfrastructuretailored for biotech and pharmaceutical companies,” said Atul Bhadwaj, Business Head at Lighthouse Canton Real Estate and Head of Projects and Business Development atNeovantageInnovationParks. “TheinaugurationofMiltenyiBiotecֱ facility and our continued expansion demonstrate our commitment to creating an enabling environment for next-generation therapies and healthcareinnovation.”
